Commentary

Video

Frequent AEs and Management Approaches for Advanced HER2+ Breast Cancer

Author(s):

Joyce A. O'Shaughnessy, MDNeil M. Iyengar, MD

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss commonly reported adverse effects from HER2-positive breast cancer treatment and appropriate management strategies for them.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Sergio A. Giralt, MD
Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, chief, Division of Breast Oncology, associate director, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Linda Vahdat, MD, MBA
Peter Forsyth, MD
Related Content
Pyrotinib Plus Metronomic Vinorelbine in HER2+ Advanced Breast Cancer | Image Credit: © Axel Kock - stock.adobe.com
September 5th 2024

Pyrotinib Plus Metronomic Vinorelbine Is Active in HER2+ Advanced Breast Cancer After Trastuzumab

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Revisit Every OncLive On Air Episode From August 2024
August 30th 2024

Revisit Every OncLive On Air Episode From August 2024

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
August 22nd 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

State of the Science Summit - Breast Cancer: Chaired by Christos Vaklavas, MD
August 29th 2024

State of the Science Summit - Breast Cancer: Chaired by Christos Vaklavas, MD

Jason A. Mouabbi, MD, of MD Anderson Cancer Center
August 26th 2024

DESTINY-Breast06 Redefines Treatment Paradigms, Calls Necessity of HER2 Testing for T-DXd into Question in HR+ Breast Cancer